Financial Performance - The company's operating revenue for the first half of 2024 was approximately ¥1.65 billion, representing a 4.26% increase compared to ¥1.59 billion in the same period last year[11]. - Net profit attributable to shareholders decreased by 16.42% to approximately ¥440.20 million from ¥526.65 million year-on-year[11]. - The net cash flow from operating activities dropped significantly by 58.13% to approximately ¥321.34 million, down from ¥767.38 million in the previous year[11]. - Basic earnings per share fell by 16.66% to ¥0.2406, compared to ¥0.2887 in the same period last year[11]. - Total assets at the end of the reporting period were approximately ¥15.64 billion, a decrease of 2.91% from ¥16.11 billion at the end of the previous year[11]. - The net assets attributable to shareholders decreased by 0.96% to approximately ¥11.25 billion from ¥11.36 billion year-on-year[11]. - The company reported a net profit of 77,379,037.09 CNY for the first half of 2024[14]. - The company reported a significant increase of 669.42% in net cash flow from investing activities, amounting to ¥1,170,760,914.36, mainly due to cash received from investment recoveries[27]. - The company reported a decrease in sales expenses to ¥122,308,324.35 from ¥159,380,059.29 in the previous year, reflecting a cost-saving strategy[96]. - The company’s tax expenses decreased to ¥85,142,182.97 from ¥125,766,327.17, indicating improved tax efficiency[97]. Market and Industry Insights - The blood products industry is a crucial segment of the biopharmaceutical sector, with significant roles in medical emergencies and specific disease treatments[15]. - The global blood products industry is highly concentrated, with the top five foreign companies holding an 80%-85% market share[16]. - The domestic blood products market is expanding due to increased healthcare coverage and an aging population, leading to a growing demand for blood products[16]. - The vaccine industry is experiencing rapid growth, driven by heightened public awareness and demand for disease prevention[16]. - The global vaccine market is dominated by four major companies, which account for over 80% of the market share[16]. - The company is positioned among leading blood product manufacturers in China, including TianTan Bio, TaiBang Bio, and Shanghai RAAS[16]. - Regulatory policies in China for blood products and vaccines are becoming stricter, enhancing industry standards and safety[16]. - The overall vaccination rate for influenza in China is approximately 3%, significantly lower than the rates in Europe and East Asia, indicating substantial growth potential in the domestic influenza vaccine market[17]. - The monoclonal antibody market in China is still in its early stages, with a projected market size of RMB 194.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 36.5% from 2020 to 2025[17]. Research and Development - The company aims to increase its R&D investment by over 10% annually during the 14th Five-Year Plan period, focusing on innovation as a core task for high-quality development[17]. - The company has established a strong research and development platform, focusing on innovative vaccines, recombinant proteins, and biosimilars, with multiple projects in various clinical trial phases[22]. - The company is advancing the clinical research of its IVIG (10%) product, which has completed Phase III trials and is in the registration application stage[21]. - The company’s subsidiary has 10 products that have obtained clinical trial approval, with 4 products currently in Phase III clinical trials and 2 in Phase I[17]. - The company has integrated its R&D resources to develop new vaccine products, including the quadrivalent flu vaccine and rabies vaccine, to strengthen its vaccine business[20]. Financial Management and Investments - The company plans to distribute a cash dividend of 3 RMB per 10 shares for the fiscal year 2023, totaling 548,634,277.80 RMB[45]. - The total amount of entrusted financial management reached CNY 425,765.53 million, with an unexpired balance of CNY 110,607.82 million[71]. - The company reported no overdue amounts or impairment provisions for entrusted financial management products[71]. - The company has not engaged in any major related party transactions or non-operating fund occupation during the reporting period[67]. - The company has not faced any penalties or corrective actions related to compliance issues during the reporting period[68]. Environmental and Social Responsibility - The company has complied with various environmental protection laws and has not faced any pollution incidents or administrative penalties during the reporting period[51]. - The company actively participates in social responsibility initiatives, including support for patients with hemophilia and educational assistance for their children[66]. - The company has established a wastewater treatment facility with a capacity of 900 m³/d and another in Chongqing with a capacity of 800 m³/d, both meeting the GB21907-2008 standards for wastewater discharge[58]. - The company has implemented an environmental emergency response plan, with updates made in September 2022 and August 2022 for different locations[61]. Corporate Governance and Shareholder Information - The company held its annual general meeting on April 19, 2024, with a participation rate of 51.02%[46]. - The total number of shares before the recent change was 1,828,780,926, with a decrease of 325,000 shares, resulting in a new total of 1,828,755,926 shares[76]. - The largest shareholder, Ankang, holds 17.85% of the shares, totaling 326,527,406 ordinary shares[81]. - The second largest shareholder, Chongqing Shengkang Biotechnology Development Co., Ltd., holds 15.01%, totaling 274,438,679 ordinary shares[81]. - The company has not undergone any bankruptcy restructuring or significant litigation matters during the reporting period[67]. Accounting and Financial Reporting - The financial report for the first half of 2024 was not audited[88]. - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial condition[123]. - The company has established materiality thresholds for significant receivables and payables, with amounts over 1 million RMB being considered significant[126]. - The company evaluates control over investees based on various factors, including the purpose of establishment and decision-making rights[130]. - The company recognizes financial assets or liabilities when it becomes a party to a financial instrument contract, using the effective interest method for amortized cost calculations[137].

证券代码：002007 证券简称：华兰生物 公告编号：2024-017 华兰生物工程股份有限公司董事会 2024年8月24日 关于全资子公司获批设置单采血浆站的公告 重庆公司将按照《血液制品管理条例》《单采血浆站管理办法》和《单采血 浆站基本标准》等法规标准，加快该单采血浆站的建设及相关执业登记手续的办 理。该单采血浆站建成并通过验收后，将有利于进一步提升公司原料血浆的供应 能力,提高公司盈利水平。公司将根据该事项的进展情况及时进行信息披露。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 华兰生物工程股份有限公司 2024年8月23日，公司全资子公司华兰生物工程重庆有限公司（以下称"重 庆公司"）收到《重庆市卫生健康委员会关于华兰生物工程重庆有限公司在丰都 县设置单采血浆站的批复》（渝卫复[2024]232号）和《重庆市卫生健康委员会 关于华兰生物工程重庆有限公司在巫山县设置单采血浆站的批复》（渝卫复 [2024]233号），重庆市卫生健康委员会同意重庆公司在丰都县和巫山县设立单 采血浆站。 ...

[ T able_StockInfo] 2024 年 07 月 09 日 证券研究报告•公司动态跟踪报告 当前价:15.15 元 华兰生物(002007)医药生物 目标价:——元(6 个月) 实控人及高管拟增持公司股份,彰显长期发展潜力 [Table_Summary 事件:1)近日公司 ] 公告董事长及部分董事增持或拟增持公司股份;2)公司发 布公告杞县、襄城单采浆站收到《单采血浆许可证》。 董事、高管增持计划彰显公司长期投资价值。公司董事长、实际控制人安康、 董事安文琪以集中竞价交易方式完成增持公司股份 45万股、1万股。此外,公 司董事长、部分董事、高管共 10人拟以自有资金于未来 6个月内增持公司股份, 合计增持数量不低于 122 万股,不高于 242 万股。此次增持计划彰显了公司董 事会成员及高管对公司长期投资价值的认可和未来发展信心。 杞县、襄城浆站获批开采,2024年浆量增长可期。根据全国第七次人口普查数 据和襄城县国民经济和社会发展统计公报,2020年杞县常住人口 93万人,2021 年襄城县常住人口 68万人。公司于 2022 年获河南省批准建设 7家新浆站,杞 县、襄城浆站系其中第六、七家获 ...

Investment Rating - The report gives a "Buy" rating for the company, with expected relative stock price growth of over 20% compared to the benchmark index within 6 months [7][10] Core Views - The company's blood products business is developing steadily, with a share buyback plan announced by the chairman and controlling shareholder [3] - Plasma collection volume is expected to maintain high growth, with all 7 plasma stations in Henan province operational, laying a solid foundation for sustained growth [5] - Influenza vaccine prices have been reduced by about 30%, which is expected to boost market penetration [6] Company Overview - Latest closing price: 15.15 yuan [1] - Total market capitalization: 27.7 billion yuan [1] - P/E ratio: 18.66 [1] - Debt-to-asset ratio: 16.7% [1] Financial Projections - Expected net profit attributable to parent company: 1.688 billion yuan in 2024, 1.923 billion yuan in 2025, and 2.152 billion yuan in 2026 [7] - Projected EPS: 0.92 yuan in 2024, 1.05 yuan in 2025, and 1.18 yuan in 2026 [7] - Forecasted revenue growth: 15.03% in 2024, 14.91% in 2025, and 13.45% in 2026 [8] Business Development - Plasma collection reached 1,342 tons in 2023, with double-digit growth expected in 2024 [5] - In Q2 2024, the company received 50 batches of albumin approvals and 31 batches of immunoglobulin approvals [5] - Influenza vaccine received 54 batches of approvals for quadrivalent vaccine and 4 batches for trivalent vaccine in H1 2024 [6] Shareholder Activity - The controlling shareholder and some directors plan to buy back 1.22-2.42 million shares within 6 months starting from July 8, 2024 [4] - The chairman and controlling shareholder have already repurchased 450,000 shares at an average price of 15.03 yuan per share [4]

证券代码：002007 证券简称：华兰生物 公告编号：2024- 016 华兰生物工程股份有限公司 关于董事长、实际控制人、部分董事增持公司股份暨董事长、 实际控制人、部分董事、高级管理人员后续增持计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： ●2024年7月8日，华兰生物工程股份有限公司（以下简称"公司"） 董事 长、实际控制人安康先生、董事安文琪女士通过深圳证券交易所系统以集中竞 价交易方式增持本公司45万股、1万股（以下简称"首次增持"），分别占公司 总股本的0.0246%、0.0005%。 ● 基于对华兰生物工程股份有限公司（以下简称"公司"）长期投资价值 的认可和未来发展信心，为提升投资者信心，维护中小投资者利益，公司实际 控制人、部分董事、高管计划自2024年7月8日（含7月8日）起6个月内通过深圳 证券交易所集中竞价方式增持公司股份，合计增持数量不低于122万股，不高于 242万股。 2、上述增持主体在本次公告前的12个月内未曾披露增持计划。 3、上述增持主体在本公告披露前6个月内不存在减持公司股份的情形。 二、增持计划 ...

证券代码：002007 证券简称：华兰生物 公告编号：2024-015 华兰生物工程股份有限公司 2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 股1个月（含1个月）以内，每10股补缴税款0.6元；持股1个月以上至1年（含1 年）的，每10股补缴税款0.3元；持股超过1年的，不需补缴税款。】 三、股权登记日与除权除息日 华兰生物工程股份有限公司2023年年度权益分派方案已获2024年4月19日召 开的2023年度股东大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配方案的情况 1、公司于2024年4月19日召开的2023年度股东大会审议通过了《关于2023 年度利润分配的议案》，公司2023年度利润分配方案为：以总股本1,828,780,926 股为基数， 向全体股东每10股派现金股利3元（含税），总计分配548,634,277.80 元；除上述现金分红外，本次分配公司不送红股，不实施资本公积金转增股本。 2、本次实施的分配方案与股东大会审议通过的分配方案一致。 3、自分配方案披露日至实施期间公司股本总额未发 ...

2、四价流感病毒裂解疫苗（成人剂型、西林瓶 0.5ml/瓶）调整至 85 元/瓶； 3、四价流感病毒裂解疫苗（儿童剂型、预充式 0.25ml/支）调整至 128 元/ 支。 上述价格均未包含储存运输费，若部分地区收取疫苗储存运输费，挂网价格 则根据储存运输费相应上调。 本次价格调整预计对公司四价流感疫苗销售收入产生不利影响，对公司业绩 的影响最终以公司披露的定期报告为准。从长远来看，价格降低有利于刺激流感 疫苗市场需求的增长，进一步提升流感疫苗接种率，扩大市场规模，带来以价换 量的市场机遇。下一步公司将通过加强内部费用控制，努力提升销量等手段消化 降价带来的压力。敬请广大投资者理性投资，注意投资风险！ 证券代码：002007 证券简称：华兰生物 公告编号：2024-014 华兰生物工程股份有限公司 关于控股子公司主要产品价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为提高流感疫苗的可及性，提升公司产品市场竞争力和市场占有率，减轻人 民群众和政府的经济负担，承担企业社会责任，结合目前市场情况，经华兰生物 工程股份有限公司控股子公司华兰生物疫苗股 ...

证券代码：002007 证券简称：华兰生物 公告编号：2024-013 华兰生物工程股份有限公司 关于公司取得单采血浆许可证的公告 机构名称：华兰生物工程股份有限公司杞县单采血浆站 业务项目：机采单采普通原料血浆、机采单采破伤风免疫原料血浆、机采单 采狂犬免疫原料血浆、机采单采乙肝免疫原料血浆 许可证号：豫卫单采血浆站字〔2024〕第11号 采浆区域：杞县 有效期限：2024年5月14日至2026年5月13日 二、华兰生物襄城单采血浆站 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 2024年5月15日，华兰生物工程股份有限公司（以下简称"公司"）下属的 华兰生物杞县单采血浆站、华兰生物襄城单采血浆站取得河南省卫生健康委员会 印发的《单采血浆许可证》。现将主要信息公告如下： 一、华兰生物杞县单采血浆站 许可证号：豫卫单采血浆站字〔2024〕第12号 采浆区域：襄城县 有效期限：2024年5月15日至2026年5月14日 上述两家单采血浆站自取得《单采血浆许可证》之日起可正式采浆。上述浆 站实现采浆将有利于提升公司原料血浆供应能力，对公司长期发展具有积极作用。 ...

血制品业务稳健，静待流感疫苗放量 华兰生物(002007)/生物制品 证券研究报告/公司点评 2024年5月8日 [Table_Industry] [评Ta级ble：_T买itle入] (维持) [公Ta司ble盈_F利in预anc测e]及 估值 市场价格：19.53 指标 2022A 2023A 2024E 2025E 2026E 营业收入（百万元） 4516.98 5341.87 6129.73 7216.10 8499.01 分析师：祝嘉琦 增长率yoy% 1.82% 18.26% 14.75% 17.72% 17.78% 执业证书编号：S0740519040001 净利润（百万元） 1076.27 1481.58 1741.03 2059.99 2412.58 电话：021-20315150 增长率yoy% -17.14% 37.66% 17.51% 18.32% 17.12% 每股收益（元） 0.59 0.81 0.95 1.13 1.32 Email：zhujq@zts.com.cn 每股现金流量 0.60 0.54 2.49 2.65 2.85 分析师：张楠 净资产收益率 9% 11% 12% ...

公 司 研 证券研究报告 究 ＃＃iinndduussttrryyIIdd＃＃ 医药生物 ＃investSuggestion＃ ＃ ＃d 华yCo 兰mp 生any＃物 （ 002007.SZ ） investSug 增持 ( 维ges持tion ）Ch 000009 ＃ title＃ 2023 年采浆大幅提升，2024 年 Q1 疫苗板块出现业绩波动 ange＃ ＃ createTime1＃ 2024年 5月 1日 投资要点 公 ＃市场ma数rk据et Data＃ ＃⚫ sum2m0a2ry3＃年 血制品稳健增长，采浆量大幅提升，疫苗制品板块增速亮眼。2023 司 日期 2024-04-30 年，公司实现营业收入 53.42 亿元，同比增长 18.26%；实现归母净利润 点 收盘价（元） 19.47 14.82亿元，同比增长37.66%；实现扣非归母净利润12.67亿元，同比增 评 总股本（百万股） 1,828.78 长41.77%；实现经营现金流净额13.46亿元，同比增长40.59%。1）血制 报 流通股本（百万股） 1,573.59 品板块：2023年公司采浆量为1342.32吨，较上年增长19.59 ...